Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • GPR
    (2)
  • Others
    (8)
Filter
Search Result
Results for "

gpr8

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    13
    TargetMol | Activity
  • Peptide Products
    4
    TargetMol | inventory
  • Recombinant Protein
    1
    TargetMol | natural
GPR84 antagonist 8
T114621445846-30-9In house
GPR84 antagonist 8 is a selective GPR84 antagonist.
  • $4,528
6-8 weeks
Size
QTY
GPR81 agonist 2
T727721143024-28-5
GPR81 agonist 2 is a potent agonist targeting the GPR81 receptor, demonstrating EC50 values of 0.023 µM for hGPR81 and 0.123 µM for hGPR109A, respectively.
  • $2,570
10-14 weeks
Size
QTY
GPR84 antagonist 3
T629182815263-05-7
GPR84 Antagonist 3 (compound 42), a potent inhibitor of the G-protein-coupled receptor 84 (GPR84), exhibits a pIC50 value of 8.28, indicating strong antagonistic activity by inhibiting GTPγS. Additionally, it possesses a favorable pharmacokinetic profile, suitable for further research and development [1].
  • $1,520
10-14 weeks
Size
QTY
GPR84 antagonist 2
T725362244269-74-5
GPR84 Antagonist 2, a potent and selective GPR84 antagonist (IC 50 = 8.95 nM), demonstrates oral activity and significantly enhances potency in calcium mobilization assays. It effectively inhibits neutrophil and macrophage chemotaxis following GPR84 activation, highlighting its research potential for ulcerative colitis.
  • $1,520
6-8 weeks
Size
QTY
GPR84 antagonist 1
T62261
GPR84 antagonist 1 is a highly selective, high-affinity competitive antagonist of human GPR84.
  • $1,470
10-14 weeks
Size
QTY
GPR88-IN-1
T79901714265-50-6
GPR88-IN-1 is a GPR88 antagonist that can be used for researching central nervous system disorders [1].
  • Inquiry Price
8-10 weeks
Size
QTY
GPR81 agonist 1
T626561620992-67-7
GPR81 agonist 1 is a potent and selective GPR81 agonist with high affinity for human and mouse GPR81, inhibiting lipolysis of differentiated 3T3-L1 adipocytes, improving insulin sensitivity and glycaemic control in mouse models of insulin resistance and diabetes, and can be used in the study of diabetes and obesity.
  • $132
In Stock
Size
QTY
GPR88 agonist 3
T865222963597-44-4
    10-14 weeks
    Inquiry
    GPR88 agonist 2
    T79902
    GPR88 agonist 2 (compound 53) is a potent, brain-penetrant agonist of GPR88, with an EC50 of 14 µM in the GPR88 cAMP functional assay [1].
    • Inquiry Price
    Size
    QTY
    Neuropeptide W-23(human)
    TP1073383415-79-0
    Neuropeptide W-23(human) (NPW-23) is an endogenous ligand for NPBW1 and NPBW2.
    • $123
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
    Neuropeptide W-23 (human) (TFA)
    T81680
    Neuropeptide W-23 (human) (NPW-23) TFA, representing the active form of Neuropeptide W, functions as an endogenous agonist for both NPBW1 (GPR7) and NPBW2 (GPR8) receptors [1].
    • Inquiry Price
    Size
    QTY
    Biotinyl-neuropeptide W-23 (human)
    T828621815618-09-7
    Biotinyl-neuropeptide W-23 (human) is a biotinylated variant of neuropeptide W-23 (human) that acts as an agonist for the NPBW1 (GPR7) and NPBW2 (GPR8) receptors [1] [2].
    • Inquiry Price
    Size
    QTY
    (Des-Bromo)-Neuropeptide B (1-23) (human)
    T83547434897-64-0
    '(Des-Bromo)-Neuropeptide B (1-23) (human)' is an agonist for orphan G-protein-coupled receptors, exhibiting a K i of 1.2 nM for GPR7 (NPBW1) and 341 nM for GPR8 (NPBW2) respectively [1].
    • Inquiry Price
    Size
    QTY